AU2001280883A1 - Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis - Google Patents

Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Info

Publication number
AU2001280883A1
AU2001280883A1 AU2001280883A AU8088301A AU2001280883A1 AU 2001280883 A1 AU2001280883 A1 AU 2001280883A1 AU 2001280883 A AU2001280883 A AU 2001280883A AU 8088301 A AU8088301 A AU 8088301A AU 2001280883 A1 AU2001280883 A1 AU 2001280883A1
Authority
AU
Australia
Prior art keywords
vaccines
protection against
diseases caused
broad spectrum
neisseria meningitidis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280883A
Other languages
English (en)
Inventor
Dan Granoff
Gregory R. Moe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Oakland Research Center
Original Assignee
CHILDREN S HOSPITAL OAKLAND RE
Childrens Hospital Oakland Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHILDREN S HOSPITAL OAKLAND RE, Childrens Hospital Oakland Research Institute filed Critical CHILDREN S HOSPITAL OAKLAND RE
Publication of AU2001280883A1 publication Critical patent/AU2001280883A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2001280883A 2000-07-27 2001-07-27 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis Abandoned AU2001280883A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22149500P 2000-07-27 2000-07-27
US60221495 2000-07-27
PCT/US2001/023842 WO2002009643A2 (en) 2000-07-27 2001-07-27 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Publications (1)

Publication Number Publication Date
AU2001280883A1 true AU2001280883A1 (en) 2002-02-13

Family

ID=22828056

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280883A Abandoned AU2001280883A1 (en) 2000-07-27 2001-07-27 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Country Status (12)

Country Link
US (2) US6936261B2 (enrdf_load_html_response)
EP (1) EP1322328B1 (enrdf_load_html_response)
JP (1) JP5511117B2 (enrdf_load_html_response)
KR (1) KR20030024811A (enrdf_load_html_response)
AU (1) AU2001280883A1 (enrdf_load_html_response)
BR (1) BRPI0112928B1 (enrdf_load_html_response)
CA (1) CA2416137C (enrdf_load_html_response)
CR (1) CR6880A (enrdf_load_html_response)
EC (1) ECSP034447A (enrdf_load_html_response)
ES (1) ES2519440T3 (enrdf_load_html_response)
MX (1) MXPA03000822A (enrdf_load_html_response)
WO (1) WO2002009643A2 (enrdf_load_html_response)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2332963C (en) 1998-05-29 2013-07-23 Chiron Corporation Combination meningitidis b/c vaccines
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
NZ545647A (en) 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
MXPA02004283A (es) 1999-10-29 2002-10-17 Chiron Spa Peptidos antigenicos neisseriales.
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
NO20002828D0 (no) * 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
KR20030024811A (ko) * 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US7615227B2 (en) 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
EP1517920A2 (en) * 2002-05-14 2005-03-30 Affitech AS Product
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
RU2359696C2 (ru) * 2002-08-02 2009-06-27 ГлаксоСмитКлайн Байолоджикалз с.а. Вакцинная композиция, содержащая трансферрин-связывающий белок и hsf из грамотрицательных бактерий
PL375408A1 (en) * 2002-08-02 2005-11-28 Glaxosmithkline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004054611A1 (en) * 2002-12-16 2004-07-01 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
PT1587537E (pt) 2003-01-30 2012-05-30 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1725256A4 (en) * 2004-02-18 2008-12-31 Univ Newcastle Res Ass VACCINE FORMULATION FOR ADMINISTRATION TO THE LUNGSSCHLEIMHAUT
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US9034345B2 (en) 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
PL2283857T3 (pl) * 2005-06-27 2020-02-28 Glaxosmithkline Biologicals Sa Kompozycja szczepionki zawierająca skoniugowane natywne polisacharydy otoczkowe N. meningitidis
US20090269362A1 (en) * 2005-07-25 2009-10-29 Sant Andrea J Method for Controlling Immunodominance
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US8414899B2 (en) * 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP5523313B2 (ja) 2007-07-03 2014-06-18 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用
AU2008272854B2 (en) * 2007-07-03 2014-03-13 Children's Hospital & Research Center At Oakland Inhibitors of polysialic acid de-N-acetylase and methods for using the same
CA2690440A1 (en) 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
EP2185576A4 (en) * 2007-08-02 2011-01-12 Childrens Hosp & Res Ct Oak FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES
BRPI0818545A2 (pt) 2007-10-19 2017-07-04 Novartis Ag formulações de vacinais meningocócicas
EP3263591B1 (en) 2008-02-21 2019-03-27 GlaxoSmithKline Biologicals S.A. Meningococcal fhbp polypeptides
CA2726512A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
AU2009287339B2 (en) * 2008-08-28 2015-11-26 The University Of Queensland Mutant bacterial glycoproteins and uses thereof
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0816284D0 (en) * 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CA2776004A1 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
ES2631977T3 (es) 2009-12-15 2017-09-07 Glaxosmithkline Biologicals Sa Suspensión homogénea de compuestos inmunopotenciadores y usos de la misma
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
KR101853513B1 (ko) 2010-03-23 2018-04-30 노파르티스 아게 감염, 염증, 호흡기 질환 등의 치료를 위해 사용되는 ｔｌｒ2 효능제로서의 화합물 (시스테인 기재 리포펩티드) 및 조성물
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
ES2654613T3 (es) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promotores para una expresión aumentada de proteínas en meningococos
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
NZ630133A (en) 2012-06-14 2016-10-28 Novartis Ag Vaccines for serogroup x meningococcus
MX2015002717A (es) 2012-09-06 2015-05-15 Novartis Ag Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
JP2016507543A (ja) 2013-02-07 2016-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 小胞を含む医薬組成物
SI3110442T1 (sl) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals S.A. Modificirani meningokokni fHbp polipeptidi
AU2017321039B2 (en) 2016-09-02 2021-03-18 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
MA50086A (fr) 2017-09-08 2020-07-15 Evelo Biosciences Inc Vésicules extracellulaires (ev) bactériennes
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202311230D0 (en) 2023-07-21 2023-09-06 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025021710A1 (en) 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
EP0449958B9 (en) 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
CA2332963C (en) 1998-05-29 2013-07-23 Chiron Corporation Combination meningitidis b/c vaccines
EP1559795A3 (en) 1998-10-09 2005-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use
US20030215469A1 (en) * 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
EP1127137B2 (en) * 1998-11-03 2013-12-25 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
JP2003527079A (ja) 1999-04-30 2003-09-16 カイロン コーポレイション ナイセリアゲノム配列およびそれらの使用方法
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
KR20030024811A (ko) * 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0024200D0 (en) 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US20050232936A1 (en) 2001-07-27 2005-10-20 Chiron Corporation Meningococcus adhesins nada, app and orf 40
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
EP1374892A1 (en) 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
PL375408A1 (en) 2002-08-02 2005-11-28 Glaxosmithkline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2608048T3 (es) * 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Vacunas polipeptídicas para protección amplia contra linajes meningocócicos hipervirulentos
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US9034345B2 (en) * 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
EP2185576A4 (en) * 2007-08-02 2011-01-12 Childrens Hosp & Res Ct Oak FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES

Also Published As

Publication number Publication date
EP1322328A2 (en) 2003-07-02
US8980285B2 (en) 2015-03-17
US20060029621A1 (en) 2006-02-09
KR20030024811A (ko) 2003-03-26
JP5511117B2 (ja) 2014-06-04
ECSP034447A (es) 2003-04-25
US6936261B2 (en) 2005-08-30
JP2004512269A (ja) 2004-04-22
CA2416137A1 (en) 2002-02-07
WO2002009643A2 (en) 2002-02-07
BRPI0112928B1 (pt) 2017-08-29
BRPI0112928B8 (enrdf_load_html_response) 2021-05-25
US20020110569A1 (en) 2002-08-15
MXPA03000822A (es) 2004-11-01
ES2519440T3 (es) 2014-11-07
CR6880A (es) 2006-08-09
WO2002009643A3 (en) 2002-05-30
EP1322328B1 (en) 2014-08-20
BR0112928A (pt) 2003-08-26
EP1322328A4 (en) 2005-07-20
CA2416137C (en) 2013-01-29

Similar Documents

Publication Publication Date Title
AU2001280883A1 (en) Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
LT2682126T (lt) Gna1870 pagrindu gaminamos pūslelių pavidalo vakcinos, skirtos plataus spektro apsaugai nuo neisseria meningitidis sukeltų ligų
AU2002353378A1 (en) Vaccine for periodontal disease
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
AU2002309156A1 (en) Methods for dental restoration
EP1437454B8 (de) Höhenverstellbarer Eckkantenschutz
AU2001258279A1 (en) Adjuvant for vaccines
AU2002353417A1 (en) Adjuvanted antigenic meningococcal compositions
AU2003270779A1 (en) Vaccine compositions and adjuvant
AU2001258550A1 (en) Insulin formulation for inhalation
AU2000279614A1 (en) Remedies for endothelin-induced diseases
AU2003229199A1 (en) Liposome vaccine formulations for fin-fish
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
AU2003264724A1 (en) Flagellin peptides as adjuvants for vaccines
AU4445201A (en) Method for administering insulin to the buccal region
HK1056312A (en) Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
AU2003900767A0 (en) Idiotypic vaccine
GB0308691D0 (en) Vaccine preparations
AU2001228863A1 (en) Remedies for ophthalmic diseases
AU2003244092A1 (en) 1ss-METHYLCARBAPENEM DERIVATIVE FOR ORAL ADMINISTRATION
AU2003278705A1 (en) Crown ether derivatives
AU2003235185A1 (en) Vaccine composition for preventing meningococcal disease
AU2001266534A1 (en) Papillomavirus vaccine
IL174699A0 (en) Vaccine for periodontal disease
AU2003906480A0 (en) Vaccine comprising mutant pilin